> ## Content Index
> Fetch the complete content index at: https://www.intercepta.ai/blog/llms.txt
> Use this file to discover other available public pages before exploring further.

# One compliant claim, exposed in other jurisdictions
- URL: https://www.intercepta.ai/blog/marketing-compliance-many-rulebooks/
- Published: 2026-09-17T08:24:18.000Z
- Updated: 2026-09-17T08:24:18.000Z
- Description: Four marketing claims, each compliant in the market it was written for, tested across lending, insurance, healthcare and real estate in six jurisdictions. No approval applied beyond its own market, and in healthcare, the format itself was lawful in some countries and prohibited in others.
- Author: Edward Sweigart
- Tags: Marketing Compliance, Regulatory, advertising compliance, continuous validation, #rail

A claim that meets one regulator’s requirements can breach the rules of the next jurisdiction where it is released. The divergence differs from one regulated sector to the next, and in some sectors, it includes the legality of the format itself.

Marketing is built on infrastructure that is global by default. A firm’s website, social media channels and approved library of claims can serve every market at once, and every market can receive the same content at the same moment. Regulation is structured by jurisdiction, since each rulebook is drafted for one jurisdiction and applies within it, and an approval obtained against one is not recognised by the next. A claim is written once and published everywhere, and with each additional market a further set of rules applies.

The pattern is consistent across the regulated industries in this piece, and its form differs in each. In financial services, a client testimonial can satisfy one regulator’s conditions in full and still need a different remediation in the other markets where it is published. A single rate figure in lending requires different prescribed content in the copy market by market. In insurance, one national approval does not cover the United States or Canada, because the United States regulates insurance advertising state by state and Canada regulates it province by province. For healthcare, the divergence is not only in the content but in the format itself, since a patient testimonial that satisfies American conditions is prohibited outright in some other major markets. In real estate, the distinction is made within a single sentence, where a claim about a home becomes a claim about an investment and the regulator can change with it.

The operating assumption for a compliance team follows from the pattern. Content compliant in one market can still carry regulatory exposure in another, and the remediation is different in each. Four chapters follow, on lending, insurance, healthcare and real estate, each built on a single worked sentence, the claim as a marketer would write it, the approval that confirms it is compliant in its own market, and the rule in another market that the approval does not satisfy. Every regulatory statement in this piece is drawn from the instrument or from the regulator’s own published text, and the sources are listed at the end.

![A figure titled ‘One compliant claim, exposed in other jurisdictions’, a four-rung ladder for lending, insurance, healthcare and real estate with a narrowing bar beside each rung, from national rulebooks to sub-national rules to the legality of the format to one sentence.](https://www.intercepta.ai/blog/content/images/2026/09/one-validated-claim-hero-narrowing-arc-2400x1400-v3.png)

Across the four sectors in the piece, the unit of divergence is smaller at each stage, from six national rulebooks in lending to two readings of one sentence in real estate.

## Lending

“They approved me at an annual percentage rate of 3.9 per cent.” In this worked example the figure is accurate, the rate is fixed and the customer is real.

In the United States, expressed as an annual percentage rate (APR), it is compliant as written under the federal rules this chapter tests. Regulation Z, which implements the Truth in Lending Act, provides, at 12 CFR 1026.24(c), that if an advertisement “states a rate of finance charge, it shall state the rate as an ‘annual percentage rate,’ using that term”. The testimonial states the rate exactly as an APR. The copy mentions no payment, so it carries none of the “triggering terms” in 1026.24(d)(1), which are the amount or percentage of any downpayment, the number of payments or period of repayment, the amount of any payment, and the amount of any finance charge. The fuller set of repayment disclosures is therefore not required, and a monthly payment would trigger them. Regulation Z is not the only rule in point. The advertised rate must be one the lender offers, and under the Federal Trade Commission (FTC, US) endorsement guides a testimonial a consumer can read as a typical outcome must be substantiated as one. The advertisement is published only once the compliance team holds the file proving the named borrower is real and was approved at 3.9 per cent, has confirmed that 3.9 per cent is a rate the lender in fact offers, and has established that it is a rate borrowers generally obtain rather than an outlier, or else the advertisement states the rate borrowers can expect. Only once that substantiation is on file is the advertisement approved in the United States.

Published unchanged in the United Kingdom, the advertisement is a financial promotion, and it is in breach. CONC 3.5.3R of the Consumer Credit sourcebook (CONC) of the Financial Conduct Authority (FCA) Handbook requires a promotion which “indicates a rate of interest or an amount relating to the cost of credit” to include a representative example, and the testimonial indicates a rate. CONC 3.5.5R sets out what the example must contain for a loan of this kind. The required items are the rate of interest and whether it is fixed or variable, the nature and amount of any other charge, the total amount of credit, the duration of the agreement, the total amount payable and the amount of each repayment, and the representative APR, a defined term meaning an APR at or below which the firm reasonably expects that credit “would be provided under at least 51% of the credit agreements which will be entered into as a result of the promotion”. The rule prescribes the presentation as well, since the example must be “accompanied by the words ‘representative example’”, with its items given equal prominence and the whole given no less prominence than any other cost information in the promotion. An advertisement that satisfies Regulation Z contains an APR but omits the representative example CONC 3.5 requires.

Australia applies its own rulebook, and the same advertisement breaches the National Credit Code. Under section 160 of the Code, Schedule 1 to the National Consumer Credit Protection Act 2009, a credit advertisement “must contain the relevant comparison rate in accordance with this Part if it contains an annual percentage rate”, and the testimonial contains one. The comparison rate is a single figure calculated on a basis the regulations lay down, for whichever designated amount and term most closely represents the typical loan being advertised, and the designated amounts and terms are set between AUD 250 over two weeks and AUD 150,000 over twenty-five years. Section 162 requires the advertisement to state clearly the name of the product and the amount and term to which each comparison rate applies, together with whether the rate is for a secured or an unsecured loan, and under section 163 the comparison rate “must be accompanied by a warning about the accuracy of the comparison rate” in the form the regulations set. Section 150(3) of the Code contains the inverse of the American trigger, since an advertisement need not contain an annual percentage rate at all “but must do so if the advertisement states the amount of any repayment”. An advertisement compliant in Australia and one compliant in the United States can quote the same 3.9 per cent and still differ on almost every other required disclosure.

In Canada a fourth rulebook applies, at the federal level. Under section 627.91 of the Bank Act, an institution “that makes a prescribed representation in an advertisement in Canada” for a product obtainable by a natural person under a credit agreement “shall disclose prescribed information in the advertisement”, and section 50 of the Financial Consumer Protection Framework Regulations sets out the detail. A representation of the interest rate, the amount of any payment or the amount of any non-interest charge is a prescribed representation, the annual percentage rate and the term of the loan are the prescribed information, and the annual percentage rate “must be presented at least as prominently as the prescribed representation and in the same manner, whether visually or aurally, or both”. The testimonial states the rate but omits the term, so it does not include what the framework prescribes. The framework binds federally regulated institutions, provincial cost-of-credit disclosure governs the other lenders, and an approval obtained in another jurisdiction does not meet its requirements.

The European Union applies the Consumer Credit Directive, the source of the United Kingdom’s representative example, and requires the same figure to be presented in a representative example stating the annual percentage rate, the total amount of credit and the total amount payable. The copy does not include this information, and the requirement is enforced nationally by each member state.

New Zealand completes the set, and its advertising standards, in the Credit Contracts and Consumer Finance Regulations 2004, apply to an advertisement distributed to the public that “refers to an interest rate or an interest charge”. Regulation 4AAAR then requires it to state “the annual interest rate or rates for the consumer credit contracts covered by the advertisement” as a percentage, the range of rates where the rate “may vary from that advertised depending on the debtor’s risk”, and, where a rate is not fixed for the term, “a statement to that effect”. A testimonial quoting one borrower’s annual percentage rate states neither the annual interest rate in the form the regulation prescribes nor, where the lender prices by risk, the range it requires, and the Financial Markets Authority (FMA) became the regulator of the regime on 1 July 2026.

The advertisement was approved in the United States, and published unchanged it satisfies none of the other five markets. Each requires its own mandatory content, and in most of them the calculation and the wording are prescribed as well, so a lender that publishes the one approved advertisement into six markets has published six regulated advertisements sharing a single rate figure, and the content it never drafted is the source of the exposure. The missing content is different in each, the representative example in the United Kingdom and the European Union, the comparison rate and its warning in Australia, the loan term in Canada and the annual interest rate and rate range in New Zealand, and none of it is supplied by the disclosures that satisfied Regulation Z. Remediation is therefore market-specific, and an approval obtained in one market is not recognised in the next.

![A six-card figure titled ‘The same rate, six different disclosures’. The claim ‘They approved me at an annual percentage rate of 3.9 per cent’ is marked approved in the United States, and each card states the further disclosure that market’s rulebook requires.](https://www.intercepta.ai/blog/content/images/2026/09/one-validated-claim-lending-six-rulebooks-2400x1400-v3.png)

One rate figure, published unchanged into six markets, is subject to six different disclosure rules, and only the United States advertisement is compliant as written under the federal rules this chapter tests.

## Insurance

“They paid my claim in three days, and my premium never went up.”

In the United Kingdom the sentence is approved against one conduct rulebook. The Insurance: Conduct of Business sourcebook (ICOBS) of the Financial Conduct Authority (FCA) Handbook applies the clear, fair and not misleading rule at ICOBS 2.2.2R, requires marketing to be clearly identifiable as marketing, and guidance added on 31 July 2026 provides that a promotion making pricing claims should be “consistent with the result reasonably expected to be achieved by the majority of customers who respond” unless the proportion of customers likely to achieve it is stated prominently. The compliance team confirms that the customer is real and that the claim was paid in three days, and reviews the premium claim with particular care, since a true sentence about one policyholder’s renewal must not become an implied claim about what other customers can expect. One conduct regulator and one conduct sourcebook govern claims of this kind, and the sentence is approved once for the whole market.

In the United States, many more rulebooks apply. Insurance advertising in the United States is regulated by the states, and the National Association of Insurance Commissioners (NAIC) exists to keep the state regimes broadly aligned. Its instruments are model laws and regulations, and its own description of the mechanism is exact, since “it is primarily through the states’ adoption of our model laws and regulations that the legal framework for insurance regulation has been largely harmonized throughout all the states”. A model such as the Advertisements of Accident and Sickness Insurance Model Regulation, Model 40, sets a testimonial standard in section 9, under which testimonials and endorsements “shall be genuine, represent the current opinion of the author, be applicable to the policy advertised and be accurately reproduced”, and the insurer using one “makes as its own” every statement it contains. The model itself has no binding force, since each state enacts its own version, edits as it enacts, and some states keep their own advertising regulations, as New York does with Insurance Regulation 34 and Regulation 34-A. The national approval process in the United Kingdom has no federal counterpart in the United States, and the sentence must be assessed separately against each state where the campaign is published.

Similarly, Canada is regulated province by province. Market conduct in insurance, advertising included, is regulated primarily by the provinces, and nationally there is a coordinating council rather than a rulebook, since the Canadian Council of Insurance Regulators (CCIR, Canada) describes itself as “an inter-jurisdictional association of insurance regulators” working on common regulatory issues. Quebec then adds two further requirements of its own, a dedicated distribution statute, the Act respecting the distribution of financial products and services, and a French-language regime for marketing material. A sentence approved once in a single jurisdiction therefore must be assessed again against the rules of every state and province where it will be published, and the remediation in New York can differ from the remediation in Quebec while the copy remains identical.

Three further rulebooks apply in the remaining markets, and the terms differ in each. In the European Union, the Insurance Distribution Directive sets the same conduct standard as the United Kingdom rule, requiring marketing to be fair, clear and not misleading and to be identifiable as marketing, so the premium claim reviewed in the United Kingdom for a misleading impression must be assessed against that standard again in each member state, through its own transposition. Australia regulates the sentence at the federal level, where the Australian Securities and Investments Commission (ASIC) administers a rule, in the Act that bears its name, under which a testimonial about a financial service is taken, in proceedings, to be misleading unless evidence to the contrary is adduced, so even for the approved sentence, the advertiser bears the evidential burden, and Regulatory Guide 234 states that the advertiser is responsible for the testimonials it publishes. New Zealand applies the fair dealing provisions in Part 2 of the Financial Markets Conduct Act, under which conduct that is likely to mislead is a breach whether or not anyone is misled, and intent is irrelevant, so the same premium impression is assessed on its likely effect, and its conduct of financial institutions regime adds a fair-conduct duty overseen by the FMA.

![A six-card figure titled ‘The same sentence, dozens of rulebooks’. The claim ‘They paid my claim in three days, and my premium never went up’ is marked approved in the United Kingdom, and each card states how the other five markets regulate it, state by state in the United States and province by province in Canada.](https://www.intercepta.ai/blog/content/images/2026/09/one-validated-claim-insurance-dozens-of-rulebooks-2400x1400-v1.png)

The sentence was approved against one conduct rulebook for the whole of the United Kingdom, and dozens of rulebooks apply across the United States and Canada, with further regimes in the European Union, Australia and New Zealand.

## Healthcare and wellness

“This treatment gave me my life back.”

The patient testimonial is a persuasive format in healthcare marketing, yet its legality depends on what the treatment is and where it is published.

In the United States, the patient story is a lawful format with conditions attached. The FTC requires health claims, testimonials included, to be substantiated by competent and reliable scientific evidence, and a patient’s experience does not substitute for the substantiation the underlying claim needs. For an advertisement promoting a prescription drug, the Food and Drug Administration (FDA) adds the fair-balance standard of its advertising rule at 21 CFR 202.1, weighing effectiveness information against side effects and contraindications, and state medical boards add their own rules for practitioner advertising. The advertisement is approved only once the compliance team holds the evidence for the treatment’s underlying claim and has confirmed that the patient and the experience are real. In the United States, the format is thus lawful, edited, evidenced and balanced.

In New Zealand the format is also lawful, and the country is, with the United States, one of the two generally cited as permitting a prescription medicine to be advertised to the public. The Medicines Act 1981 allows the advertisement, subject to the mandatory information the Medicines Regulations require, and the claims it makes are subject to the self-regulatory Therapeutic and Health Advertising Code of New Zealand’s Advertising Standards Authority, revised for 2026\. The patient story is therefore lawful in New Zealand as in the United States, edited and evidenced.

Australia prohibits the format across whole classes of marketing. Under section 133 of the Health Practitioner Regulation National Law, advertising of a regulated health service must not “use testimonials or purported testimonials about the service or business”. The prohibition is categorical, and the word “purported” covers copy merely presented as a patient story. For therapeutic goods, the Therapeutic Goods Administration (TGA, Australia) enforces the Therapeutic Goods Advertising Code, whose Part 6 restricts testimonials and endorsements, barring them from anyone engaged in producing, marketing or supplying the goods, including anyone who has received valuable consideration for the testimonial. No quantity of evidence makes the sentence lawful where the format itself is barred, because the fault is the format rather than the substantiation.

The United Kingdom prohibits the prescription-only case for advertising to the public. Regulation 284 of the Human Medicines Regulations 2012, among the rules governing advertising to the public, provides that “A person may not publish an advertisement that is likely to lead to the use of a prescription only medicine.” The question of how to condition a patient story about such a medicine therefore never arises, because the advertisement itself is the breach. The European Union mandates the same outcome, since Article 88 of Directive 2001/83/EC requires member states to “prohibit the advertising to the general public” of medicinal products that “are available on medical prescription only”, within the title that governs medicines advertising across Articles 86 to 100\. In Canada, by contrast, a prescription medicine may be advertised to the public but solely by its name, price and quantity under the Food and Drug Regulations, C.01.044, so a patient testimonial cannot appear and the sentence is unlawful.

The divergence here is in the legality of the format itself.

![A six-card figure titled ‘The same testimonial, lawful or prohibited’. The claim ‘This treatment gave me my life back’ is lawful with conditions in the United States and New Zealand, prohibited for a prescription-only medicine in the United Kingdom and the European Union, unlawful for a prescription medicine in Canada, and barred outright in Australia as a testimonial about a regulated health service.](https://www.intercepta.ai/blog/content/images/2026/09/one-validated-claim-healthcare-format-legality-2400x1400-v3.png)

The same patient testimonial is lawful with conditions in the United States and New Zealand, prohibited for prescription-only medicines in the United Kingdom and the European Union, unlawful for a prescription medicine in Canada, and barred outright in Australia as a testimonial about a regulated health service.

## Real estate

“A beautiful home, and prices in the neighbourhood have doubled in five years.”

The sentence is an estate agent’s, combining a description of the property with a factual claim about local prices. In the United Kingdom, it is approved once for the whole market. Estate agency practice is regulated by the Estate Agents Act 1979 regime under National Trading Standards oversight, and unfair commercial practices are governed UK-wide by the Digital Markets, Competition and Consumers Act 2024, in force for this purpose since 6 April 2025\. The advertising itself is within the remit of the Advertising Standards Authority (ASA) under the Committee of Advertising Practice (CAP) Code, the inverse of the financial-services position, in which technical claims by regulated firms fall outside that remit. The price claim is substantiated against sales data before it is published, and the approval applies across the United Kingdom at the consumer-protection level, with one caution written into the copy plan, since Scotland has its own marketing and transaction requirements, the Home Report among them, and the single-rulebook description is true of that regime rather than of every transactional requirement.

As with insurance, licence-law advertising is regulated by the states in both the United States and Australia, and by the provinces in Canada, each with its own identification rules and rules on price advertising. The European Union sets a common minimum standard through the Unfair Commercial Practices Directive applied through each member state’s own consumer law, and New Zealand regulates the same conduct through the Real Estate Agents Act 2008 and the Fair Trading Act.

One detail illustrates the whole argument, since in New South Wales an agent may not advertise “offers over”, because underquoting law bans the phrase, while in Scotland “offers over” is a standard way of marketing a house. The same two words are a convention in one market and a breach in another. New Zealand regulates the same underquoting conduct, since a “buyer enquiry over” price set below the seller’s minimum can be a misleading representation under the Fair Trading Act.

The real distinction in this chapter is drawn within the sentence itself. Read as praise for a home, the second clause is a price-history claim, governed in Australia by state agent rules and by the consumer law’s provisions on representations about the sale of land. Taken instead as a reason to buy in the area as an investment, the same clause becomes an investment representation, and the applicable regime can change with it, since schemes and financial products belong to the Corporations Act 2001 and to ASIC (Australia), which named property investment schemes among its 2025 enforcement priorities. Calling the house a sound investment does not by itself change which rulebook applies to the sentence, since direct property is not a financial product and an agent’s communication remains within consumer law. Reused in a property scheme’s offer document, or in an offer of a financial product, the same copy is governed by the financial regime. Jurisdiction is not defined by country alone, and within one country more than one regime can apply to the same words.

![A two-column figure titled ‘The same two words, opposite rules’. ‘Offers over’ is prohibited in an agent’s advertisement in New South Wales under underquoting law and is a standard way a home is marketed in Scotland.](https://www.intercepta.ai/blog/content/images/2026/09/one-validated-claim-re-offers-over-2400x1400-v3.png)

“Offers over” is banned in agent advertising in New South Wales and is a standard way a home is marketed in Scotland, since property advertising is regulated market by market.

## The operating assumption

The four chapters share one assumption. A claim that meets the rules of the market it was written for can still be exposed in the next, and the remediation differs by market and by sector. The unit is smaller in each successive chapter, from countries in lending, to states and provinces in insurance and real estate, to the legality of the format in healthcare, and finally to two readings of one sentence.

Two published references contain the working detail, [The Practitioner’s Marketing Compliance Playbook for Regulated Industries](https://www.intercepta.ai/playbook-library?utm%5Fsource=blog&utm%5Fmedium=cta&utm%5Fcampaign=marketing-compliance-many-rulebooks-20260917&utm%5Fcontent=inline), and [The Pre-Publication Guide to AI-Generated Marketing Content](https://www.intercepta.ai/pre-publish-guide?utm%5Fsource=blog&utm%5Fmedium=cta&utm%5Fcampaign=marketing-compliance-many-rulebooks-20260917&utm%5Fcontent=inline). The first covers the regulated verticals in turn, and the second sets out the pre-publication questions as a working list.

The four sentences in this piece were marketing’s claims, approved as compliant in the market they were designed for, and no approval applied beyond its own market. Between them, the sentences were subject to six lending rulebooks, insurance requirements set state by state, province by province and nation by nation, a healthcare format lawful in some countries and prohibited in others, and a regulator that changed with the reading of a single sentence. A team publishing one library of claims into many markets must manage every market-and-rule combination at once and at the speed marketing operates. A manual process is exposed to failure at that scale.

## Validate before you publish. Keep the record.

Across four sectors and six jurisdictions the pattern was the same. A claim approved in the market it was written for was subject to a different rulebook in each of the others, in lending and healthcare, it was in breach, and the remediation differed in each market. Intercepta AI was built for this problem, since it validates each claim against every jurisdiction it covers where the content will be published rather than only the one it was written for, and it does so before publication.

The scanner covers 1,100+ regulatory rules across the United States, United Kingdom, European Union, Canada, Australia and New Zealand, and each scan returns a documented report that maps each issue to the specific regulation it references, with remediation guidance for your compliance team to review. Marketing teams validate before publication, compliance teams hold a documented regulatory record, and every decision on every finding remains in the remit of your compliance team.

## Sources

### Statutes and rules

- [Truth in Lending Act; Regulation Z, 12 CFR 1026.24, Advertising.](https://www.ecfr.gov/current/title-12/chapter-X/part-1026/subpart-C/section-1026.24?ref=intercepta.ai)
- [Financial Conduct Authority Handbook, Consumer Credit sourcebook, CONC 3.5](https://www.handbook.fca.org.uk/handbook/CONC/3/5.html?ref=intercepta.ai), and [Glossary, representative APR.](https://www.handbook.fca.org.uk/glossary/G3354?ref=intercepta.ai)
- [National Consumer Credit Protection Act 2009 (Cth), Schedule 1, National Credit Code, sections 150 and 159 to 163; National Consumer Credit Protection Regulations 2010, designated amounts and terms.](https://www.legislation.gov.au/C2009A00134/latest?ref=intercepta.ai)
- [Bank Act (Canada), sections 627.9 and 627.91](https://laws-lois.justice.gc.ca/eng/acts/B-1.01/page-71.html?ref=intercepta.ai); [Financial Consumer Protection Framework Regulations, SOR/2021-181, section 50.](https://laws-lois.justice.gc.ca/eng/regulations/SOR-2021-181/FullText.html?ref=intercepta.ai)
- [Directive (EU) 2023/2225 on credit agreements for consumers (Consumer Credit Directive), Article 8, applicable from 20 November 2026](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32023L2225&ref=intercepta.ai); [Directive 2008/48/EC, Article 4.](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32008L0048&ref=intercepta.ai)
- [Credit Contracts and Consumer Finance Act 2003 (New Zealand), section 9C; Credit Contracts and Consumer Finance Regulations 2004, advertising standards, regulation 4AAAR; Responsible Lending Code.](https://www.legislation.govt.nz/regulation/public/2004/0240/latest/whole.html?ref=intercepta.ai)
- [Financial Conduct Authority Handbook, Insurance: Conduct of Business sourcebook, ICOBS 2.2, including the pricing-claims guidance added 31 July 2026.](https://www.handbook.fca.org.uk/handbook/ICOBS/2/2.html?ref=intercepta.ai)
- New York Codes, Rules and Regulations, 11 NYCRR 215 (Insurance Regulation 34) and 11 NYCRR 219 (Insurance Regulation 34-A).
- [Act respecting the distribution of financial products and services, CQLR c D-9.2 (Quebec).](https://www.legisquebec.gouv.qc.ca/en/document/cs/D-9.2?ref=intercepta.ai)
- [Charter of the French Language, CQLR c C-11 (Quebec), section 58.](https://www.oqlf.gouv.qc.ca/office/communiques/2015/20150526%5Fpublicite%5Fcommerciale.html?ref=intercepta.ai)
- [Directive (EU) 2016/97 on insurance distribution, Article 17.](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016L0097&ref=intercepta.ai)
- [Australian Securities and Investments Commission Act 2001 (Cth), section 12DB.](https://www.legislation.gov.au/C2004A00819/latest?ref=intercepta.ai)
- [Financial Markets Conduct Act 2013 (New Zealand), Part 2; Financial Markets (Conduct of Institutions) Amendment Act 2022 (New Zealand).](https://www.legislation.govt.nz/act/public/2013/0069/latest/DLM4090947.html?ref=intercepta.ai)
- [Health Practitioner Regulation National Law (Australia), section 133.](https://www.ahpra.gov.au/Resources/Advertising-hub?ref=intercepta.ai)
- [Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021, Schedule 1, Part 6, section 24.](https://www.legislation.gov.au/F2021L01661/latest/text?ref=intercepta.ai)
- [Human Medicines Regulations 2012, regulation 284.](https://www.legislation.gov.uk/uksi/2012/1916/regulation/284?ref=intercepta.ai)
- [Directive 2001/83/EC on the Community code relating to medicinal products for human use, Articles 86 to 100.](https://www.legislation.gov.uk/eudr/2001/83/article/88?ref=intercepta.ai)
- [Food and Drug Administration, prescription-drug advertisements, 21 CFR 202.1.](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-202/section-202.1?ref=intercepta.ai)
- [Food and Drugs Act (Canada), section 3 and Schedule A.1; Food and Drug Regulations, C.01.044.](https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,%5Fc.%5F870/section-C.01.044.html?ref=intercepta.ai)
- [Medicines Act 1981 (New Zealand) and Medicines Regulations 1984 (New Zealand).](https://www.legislation.govt.nz/act/public/1981/0118/latest/whole.html?ref=intercepta.ai)
- [Estate Agents Act 1979; Digital Markets, Competition and Consumers Act 2024, Part 4, Chapter 1.](https://www.legislation.gov.uk/ukpga/2024/13/section/226?ref=intercepta.ai)
- [Housing (Scotland) Act 2006, Part 3.](https://www.legislation.gov.uk/asp/2006/1/part/3?ref=intercepta.ai)
- [Property and Stock Agents Act 2002 (New South Wales), sections 73 and 73A; Sale of Land Act 1962 (Victoria).](https://legislation.nsw.gov.au/view/whole/html/inforce/current/act-2002-066?ref=intercepta.ai)
- [Australian Consumer Law, Schedule 2 to the Competition and Consumer Act 2010 (Cth), section 30; Corporations Act 2001 (Cth), managed investment scheme provisions.](https://classic.austlii.edu.au/au/legis/cth/consol%5Fact/caca2010265/sch2.html?ref=intercepta.ai)
- California Business and Professions Code, section 10140.6; Texas Real Estate Commission Rules 535.154 and 535.155; New York 19 NYCRR 175.25.
- [Directive 2005/29/EC on unfair commercial practices, Articles 3(9), 6 and 7.](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32005L0029&ref=intercepta.ai)
- [Real Estate Agents Act 2008 (New Zealand)](https://www.legislation.govt.nz/act/public/2008/0066/latest/whole.html?ref=intercepta.ai); [Fair Trading Act 1986 (New Zealand), sections 12A and 40.](https://www.legislation.govt.nz/act/public/1986/0121/latest/whole.html?ref=intercepta.ai)

### Regulator guidance and programmes

- [National Association of Insurance Commissioners, model laws programme; Advertisements of Accident and Sickness Insurance Model Regulation, Model 40.](https://content.naic.org/model-laws?ref=intercepta.ai)
- [Canadian Council of Insurance Regulators, mandate statement.](https://www.ccir-ccrra.org/?ref=intercepta.ai)
- [Australian Health Practitioner Regulation Agency and the National Boards, Guidelines for advertising a regulated health service.](https://www.ahpra.gov.au/Resources/Advertising-hub?ref=intercepta.ai)
- [Federal Trade Commission, Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR Part 255.](https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255?ref=intercepta.ai)
- [Federal Trade Commission, Health Products Compliance Guidance (December 2022).](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance?ref=intercepta.ai)
- [Committee of Advertising Practice Code.](https://www.asa.org.uk/codes-and-rulings/advertising-codes/non-broadcast-code.html?ref=intercepta.ai)
- [National Trading Standards, Estate and Letting Agency Teams.](https://www.nationaltradingstandards.uk/work-areas/estate-agency-team/?ref=intercepta.ai)
- [NSW Fair Trading, price estimation and underquoting guidance (updated 8 July 2026).](https://www.nsw.gov.au/housing-and-construction/buying-and-selling-property/selling-a-property/price-estimation-and-underquoting?ref=intercepta.ai)
- [Scottish Government, mygov.scot, Buying a home: the legal process.](https://www.mygov.scot/buy-home?ref=intercepta.ai)
- [Australian Securities and Investments Commission, enforcement priorities 2025.](https://www.asic.gov.au/about-asic/asic-investigations-and-enforcement/asic-enforcement-priorities?ref=intercepta.ai)
- [Australian Securities and Investments Commission, Regulatory Guide 234, Advertising financial products and services.](https://www.asic.gov.au/regulatory-resources/find-a-document/regulatory-guides/rg-234-advertising-financial-products-and-services-including-credit?ref=intercepta.ai)
- [New Zealand Advertising Standards Authority, Therapeutic and Health Advertising Code (2026).](https://asa.co.nz/codes/codes/therapeutic-and-health-advertising-code/?ref=intercepta.ai)
- [Real Estate Council of Ontario](https://www.reco.on.ca/?ref=intercepta.ai); [Organisme d’autoréglementation du courtage immobilier du Québec.](https://www.oaciq.com/?ref=intercepta.ai)